Drug Profile
Research programme: DNA vaccines - GlaxoSmithKline/Innovata
Latest Information Update: 21 Apr 2011
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 09 Aug 2007 Preclinical trials in Undefined indication in United Kingdom (PO)